Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast
Influenza Vaccine Market Overview
Last few years have seen renewed interest in the vaccines market, overcoming the prevailing view that vaccines are a low-margin business with high barriers to entry. The flu vaccines market has been at the forefront of this trend, partially fuelled by the fear of an impending pandemic. As a result global influenza vaccine market has experienced phenomenal growth in recent years at a compound annual growth rate of more than 65% between 2008 and 2010. This growth was mainly driven by the global spread of H1N1 influenza. But in the year 2011 H1N1 pandemic flu vaccine market declined due to waning threat of swine flu disease. However seasonal influenza vaccine market is predicted to grow year on year and cross US$ 4 Billion by 2015.
From our research findings Unites States is the largest market for influenza vaccine market in 2010. In seasonal influenza vaccine brands like Fluarix & Flulaval had highest sales for 2010. Unlike some other pharmaceutical products, influenza vaccines are equally important in both developed and developing nations. In the developing countries, dealing with infectious diseases remains the highest priority in healthcare. It is predicted that in the next 5-6 years seasonal influenza vaccine sales would increase significantly.
Renub Research report entitled “Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast” critically examines the influenza vaccines market through a comprehensive review of information. This report provides market prospects, Key products detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and challenges, including revenue of key players from seasonal and H1N1 influenza vaccine as well as Strengths and Weakness analysis of key players in influenza vaccine segment.
This report examines the following markets for influenza vaccines:
This section covers the key facts about the major companies that play an important role in Influenza Vaccine Market. The companies analyzed in this section are – GlaxoSmithKline, AstraZeneca, Novartis AG and Sanofi Pasteur. All the companies have been analyzed from three headings
1) Revenue of the company from influenza vaccines (swine flu & seasonal flu)
2) Strength of the company in influenza vaccine market
3) Weakness of the company in influenza vaccine market
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
Information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.
Last few years have seen renewed interest in the vaccines market, overcoming the prevailing view that vaccines are a low-margin business with high barriers to entry. The flu vaccines market has been at the forefront of this trend, partially fuelled by the fear of an impending pandemic. As a result global influenza vaccine market has experienced phenomenal growth in recent years at a compound annual growth rate of more than 65% between 2008 and 2010. This growth was mainly driven by the global spread of H1N1 influenza. But in the year 2011 H1N1 pandemic flu vaccine market declined due to waning threat of swine flu disease. However seasonal influenza vaccine market is predicted to grow year on year and cross US$ 4 Billion by 2015.
From our research findings Unites States is the largest market for influenza vaccine market in 2010. In seasonal influenza vaccine brands like Fluarix & Flulaval had highest sales for 2010. Unlike some other pharmaceutical products, influenza vaccines are equally important in both developed and developing nations. In the developing countries, dealing with infectious diseases remains the highest priority in healthcare. It is predicted that in the next 5-6 years seasonal influenza vaccine sales would increase significantly.
Renub Research report entitled “Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast” critically examines the influenza vaccines market through a comprehensive review of information. This report provides market prospects, Key products detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and challenges, including revenue of key players from seasonal and H1N1 influenza vaccine as well as Strengths and Weakness analysis of key players in influenza vaccine segment.
This report examines the following markets for influenza vaccines:
- Global Influenza vaccine market (2005 - 2015)
- Global Seasonal influenza vaccine market has been covered from (2003 – 2015)
- Global Swine Flu (H1N1) influenza vaccine market has been covered from (2009 – 2012)
- Top 7 Countries (United States, Germany, France, Italy, Spain, United Kingdom, Japan) seasonal vaccine market data from (2005 – 2015)
- Top Brands Seasonal influenza vaccine market performance (Fluarix, Afluria, Flumist, Influvac) market performance and forecast
- Top companies Swine Flu vaccine market performance (AstraZeneca, GlaxoSmithKline, Novartis, Sanofi-Pasteur)
This section covers the key facts about the major companies that play an important role in Influenza Vaccine Market. The companies analyzed in this section are – GlaxoSmithKline, AstraZeneca, Novartis AG and Sanofi Pasteur. All the companies have been analyzed from three headings
1) Revenue of the company from influenza vaccines (swine flu & seasonal flu)
2) Strength of the company in influenza vaccine market
3) Weakness of the company in influenza vaccine market
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
Information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.
1. EXECUTIVE SUMMARY
2. WORLDWIDE INFLUENZA VACCINE & FUTURE MARKET
2.1 Worldwide Seasonal Influenza Vaccine & Future Market
2.2 Global Swine Flu (H1N1) Influenza Vaccine & Future Market
2.2.1 Global Pandemic Influenza Occur (1918 - 2009)
2.2.2 Country wise Swine Flu Vaccine Dose Order (2009)
2.3 Merger and Acquisition in Influenza Vaccine Market
3. GEOGRAPHICAL DISTRIBUTION – SEASONAL INFLUENZA VACCINE MARKET (2005 TO 2015)
3.1 United States Seasonal Influenza Vaccine Market
3.2 Germany Seasonal Influenza Vaccine Market
3.3 France Seasonal Influenza Vaccine Market
3.4 Italy Seasonal Influenza Vaccine Market
3.5 Spain Seasonal Influenza Vaccine Market
3.6 United Kingdom Seasonal Influenza Vaccine Market
3.7 Japan Seasonal Influenza Vaccine Market
4. WORLDWIDE – SEASONAL INFLUENZA VACCINE BRAND MARKET & FORECAST PIPELINE ANALYSIS
4.1 Fluarix & Flulaval - Sales Performance & Forecast
4.2 Afluria - Past, Present and Future Sales Performance
4.3 FluMist – Past, Present & Future Sales Performance
4.4 Influvac - Sales Performance & Future Forecast
5. SWINE FLU VACCINE MARKET ANALYSIS – COMPETITIVE LANDSCAPE
5.1 AstraZeneca Swine Flu Vaccine Sales Performance
5.2 GlaxoSmithKline Swine Flu Vaccine Sales Performance
5.3 Novartis Swine Flu Vaccines Sales Performance
5.4 Sanofi-Pasteur Swine Flu Vaccine Sales Performance
6. GROWTH DRIVERS IN THE INFLUENZA VACCINES MARKET
6.1 Growing Prevalence of Influenza
6.2 Emerging Vaccine Technologies
6.3 Effective Communication Strategies
6.4 Compliance with Vaccination
6.5 Vaccines most Cost Effective Means of Disease Prevention
7. CHALLENGES FOR INFLUENZA VACCINE MARKET
7.1 Barriers to Optimal use of Licensed Vaccines
7.1.1 Technical Obstacles
7.1.2 Economic Obstacles
7.1.3 Cultural Obstacles
7.2 Complexity of Influenza Vaccine Development & Approval System Thwarts Product Development
7.2.1 Legal Obstacles
7.2.2 General Technical Barriers
7.2.3 Economic Barriers
7.2.4 Regulatory Barriers
7.3 Shortening the Timeline for Vaccine Development
8. COMPANY ANALYSIS
8.1 GlaxoSmithKline
8.1.1 GSK Influenza Vaccine Revenue
8.1.2 GSK Influenza Vaccine Strengths
8.1.3 GSK Influenza Vaccine Weakness
8.2 AstraZeneca
8.2.1 AstraZeneca Influenza Vaccine Revenue
8.2.2 AstraZeneca Influenza Vaccine Strengths
8.2.3 Astrazeneca Influenza Vaccine Weakness
8.3 Novartis AG
8.3.1 Novartis AG Influenza Vaccine Strengths
8.3.2 Novartis AG Influenza Vaccine Weakness
8.4 Sanofi Pasteur
8.4.1 Sanofi-Pasteur Influenza Vaccine Revenue
8.4.2 Sanofi-Pasteur Influenza Vaccine Strengths
8.4.3 Sanofi-Pasteur Influenza Vaccine Weakness
2. WORLDWIDE INFLUENZA VACCINE & FUTURE MARKET
2.1 Worldwide Seasonal Influenza Vaccine & Future Market
2.2 Global Swine Flu (H1N1) Influenza Vaccine & Future Market
2.2.1 Global Pandemic Influenza Occur (1918 - 2009)
2.2.2 Country wise Swine Flu Vaccine Dose Order (2009)
2.3 Merger and Acquisition in Influenza Vaccine Market
3. GEOGRAPHICAL DISTRIBUTION – SEASONAL INFLUENZA VACCINE MARKET (2005 TO 2015)
3.1 United States Seasonal Influenza Vaccine Market
3.2 Germany Seasonal Influenza Vaccine Market
3.3 France Seasonal Influenza Vaccine Market
3.4 Italy Seasonal Influenza Vaccine Market
3.5 Spain Seasonal Influenza Vaccine Market
3.6 United Kingdom Seasonal Influenza Vaccine Market
3.7 Japan Seasonal Influenza Vaccine Market
4. WORLDWIDE – SEASONAL INFLUENZA VACCINE BRAND MARKET & FORECAST PIPELINE ANALYSIS
4.1 Fluarix & Flulaval - Sales Performance & Forecast
4.2 Afluria - Past, Present and Future Sales Performance
4.3 FluMist – Past, Present & Future Sales Performance
4.4 Influvac - Sales Performance & Future Forecast
5. SWINE FLU VACCINE MARKET ANALYSIS – COMPETITIVE LANDSCAPE
5.1 AstraZeneca Swine Flu Vaccine Sales Performance
5.2 GlaxoSmithKline Swine Flu Vaccine Sales Performance
5.3 Novartis Swine Flu Vaccines Sales Performance
5.4 Sanofi-Pasteur Swine Flu Vaccine Sales Performance
6. GROWTH DRIVERS IN THE INFLUENZA VACCINES MARKET
6.1 Growing Prevalence of Influenza
6.2 Emerging Vaccine Technologies
6.3 Effective Communication Strategies
6.4 Compliance with Vaccination
6.5 Vaccines most Cost Effective Means of Disease Prevention
7. CHALLENGES FOR INFLUENZA VACCINE MARKET
7.1 Barriers to Optimal use of Licensed Vaccines
7.1.1 Technical Obstacles
7.1.2 Economic Obstacles
7.1.3 Cultural Obstacles
7.2 Complexity of Influenza Vaccine Development & Approval System Thwarts Product Development
7.2.1 Legal Obstacles
7.2.2 General Technical Barriers
7.2.3 Economic Barriers
7.2.4 Regulatory Barriers
7.3 Shortening the Timeline for Vaccine Development
8. COMPANY ANALYSIS
8.1 GlaxoSmithKline
8.1.1 GSK Influenza Vaccine Revenue
8.1.2 GSK Influenza Vaccine Strengths
8.1.3 GSK Influenza Vaccine Weakness
8.2 AstraZeneca
8.2.1 AstraZeneca Influenza Vaccine Revenue
8.2.2 AstraZeneca Influenza Vaccine Strengths
8.2.3 Astrazeneca Influenza Vaccine Weakness
8.3 Novartis AG
8.3.1 Novartis AG Influenza Vaccine Strengths
8.3.2 Novartis AG Influenza Vaccine Weakness
8.4 Sanofi Pasteur
8.4.1 Sanofi-Pasteur Influenza Vaccine Revenue
8.4.2 Sanofi-Pasteur Influenza Vaccine Strengths
8.4.3 Sanofi-Pasteur Influenza Vaccine Weakness
LIST OF FIGURES
Figure 2 1: Worldwide – Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 2 2: Worldwide – Forecast for Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 2 3: Worldwide – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 2 4: Worldwide – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 2 5: Worldwide – Swine Flu (H1N1) Influenza Vaccine Market & Forecast (Million US$), 2009 – 2011
Figure 3 1: United-States – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 2: United States – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 3: Germany – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 4: Germany – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 5: France – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 6: France – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 7: Italy – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 8: Italy – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 9: Spain – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 10: Spain – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 11: United Kingdom – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 12: United Kingdom – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 13: Japan – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 14: Japan – Forecast for Seasonal Influenza vaccine Market (Million US$), 2011 – 2015
Figure 4 1: Worldwide – Fluarix & Flulaval Vaccine Market (Million US$), 2007 – 2010
Figure 4 2: Worldwide – Forecast for Fluarix & Flulaval Vaccine Market (Million US$), 2011 – 2015
Figure 4 3: Worldwide – Afluria Vaccine Market (Million US$), 2008 – 2010
Figure 4 4: Worldwide – Forecast for Afluria Vaccine Market (Million US$), 2011 – 2015
Figure 4 5: Worldwide – Flumist Vaccine Market (Million US$), 2007 – 2010
Figure 4 6: Worldwide – Forecast for Flumist Vaccine Market (Million US$), 2011 – 2015
Figure 4 7: Worldwide – Influvac Vaccine Market (Million US$), 2006 – 2009
Figure 5 1: Astrazeneca – Swine Flu Vaccine Sales Performance & Future forecast (Million US$), 2009 – 2011
Figure 5 2: GSK – Swine Flu Vaccine Sales Performance & Future Forecast (Million US$), 2009 – 2011
Figure 5 3: Novartis – Swine Flu Vaccine Sales Performance & Future forecast (Million US$), 2009 – 2010
Figure 5 4: Sanofi Pasteur – Swine Flu Vaccine Sales Performance (Million US$), 2008 – 2010
Figure 9 1: Sanofi Pasteur – Influenza Vaccine Revenue (Million US$), 2007 – 2010
Figure 2 1: Worldwide – Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 2 2: Worldwide – Forecast for Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 2 3: Worldwide – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 2 4: Worldwide – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 2 5: Worldwide – Swine Flu (H1N1) Influenza Vaccine Market & Forecast (Million US$), 2009 – 2011
Figure 3 1: United-States – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 2: United States – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 3: Germany – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 4: Germany – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 5: France – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 6: France – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 7: Italy – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 8: Italy – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 9: Spain – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 10: Spain – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 11: United Kingdom – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 12: United Kingdom – Forecast for Seasonal Influenza Vaccine Market (Million US$), 2011 – 2015
Figure 3 13: Japan – Seasonal Influenza Vaccine Market (Million US$), 2005 – 2010
Figure 3 14: Japan – Forecast for Seasonal Influenza vaccine Market (Million US$), 2011 – 2015
Figure 4 1: Worldwide – Fluarix & Flulaval Vaccine Market (Million US$), 2007 – 2010
Figure 4 2: Worldwide – Forecast for Fluarix & Flulaval Vaccine Market (Million US$), 2011 – 2015
Figure 4 3: Worldwide – Afluria Vaccine Market (Million US$), 2008 – 2010
Figure 4 4: Worldwide – Forecast for Afluria Vaccine Market (Million US$), 2011 – 2015
Figure 4 5: Worldwide – Flumist Vaccine Market (Million US$), 2007 – 2010
Figure 4 6: Worldwide – Forecast for Flumist Vaccine Market (Million US$), 2011 – 2015
Figure 4 7: Worldwide – Influvac Vaccine Market (Million US$), 2006 – 2009
Figure 5 1: Astrazeneca – Swine Flu Vaccine Sales Performance & Future forecast (Million US$), 2009 – 2011
Figure 5 2: GSK – Swine Flu Vaccine Sales Performance & Future Forecast (Million US$), 2009 – 2011
Figure 5 3: Novartis – Swine Flu Vaccine Sales Performance & Future forecast (Million US$), 2009 – 2010
Figure 5 4: Sanofi Pasteur – Swine Flu Vaccine Sales Performance (Million US$), 2008 – 2010
Figure 9 1: Sanofi Pasteur – Influenza Vaccine Revenue (Million US$), 2007 – 2010
LIST OF TABLES
Table 2 1: Worldwide – Pandemic Influenza Vaccine Dose Orders (Million), 2009
Table 2 2: Worldwide – M&A Influenza Vaccine (Million US$), 2003, 2005, 2007, 2009 & 2010
Table 3 1: United States – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 2: Germany – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 3: France – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 4: Italy – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 5: Spain – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 6: United Kingdom – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 7: Japan – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 6 1: United States H1N1 – Related Hospitalizations and Deaths, By Age Group, April 2009 – February 13, 2010
Table 6 2: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations
Table 6 3: Seasonal Influenza Vaccination Compliance
Table 6 4: Pandemic Flu Vaccination Compliance
Table 6 5: Major Literature Findings Relevant to Influenza
Table 8 1: GlaxoSmithKline – Influenza Vaccine Revenue (Million US$), 2007 – 2010
Table 8 2: AstraZeneca – Influenza Vaccine Revenue (Million US$), 2007 – 2010
Table 2 1: Worldwide – Pandemic Influenza Vaccine Dose Orders (Million), 2009
Table 2 2: Worldwide – M&A Influenza Vaccine (Million US$), 2003, 2005, 2007, 2009 & 2010
Table 3 1: United States – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 2: Germany – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 3: France – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 4: Italy – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 5: Spain – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 6: United Kingdom – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 3 7: Japan – Population (Million), 2005 – 2015, 2020, 2025, 2030, 2035, 2040, 2045 & 2050
Table 6 1: United States H1N1 – Related Hospitalizations and Deaths, By Age Group, April 2009 – February 13, 2010
Table 6 2: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations
Table 6 3: Seasonal Influenza Vaccination Compliance
Table 6 4: Pandemic Flu Vaccination Compliance
Table 6 5: Major Literature Findings Relevant to Influenza
Table 8 1: GlaxoSmithKline – Influenza Vaccine Revenue (Million US$), 2007 – 2010
Table 8 2: AstraZeneca – Influenza Vaccine Revenue (Million US$), 2007 – 2010
